Share This:
https://ntp.niehs.nih.gov/go/5937

TDMS Study 96007-05 Pathology Tables

NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03
Route: GAVAGE                                                                                                     Time: 11:23:01

                                                         FINAL #3/RATS




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  57117-31-4

       Lock Date:  07/25/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include All

































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          98           98           98           98           98           98           
  Early Deaths                                                                                                                      
    Natural Death                                      7           10           10            8           14           11           
    Moribund Sacrifice                                21           20           17           19           19           19           
    Dosing Accident                                                 1            2            1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                25           22           24           25           20           23           
                                                                                                                                    
  Animals Examined Microscopically                    53           53           53           53           53           53           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (53)         (53)         (53)         (53)         (51)         (53)         
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
   Intestine Large, Rectum                            (53)         (53)         (53)         (53)         (52)         (53)         
      Carcinoma, Metastatic, Uterus                                                                                     1 (2%)      
   Intestine Large, Cecum                             (53)         (53)         (53)         (52)         (51)         (53)         
   Intestine Small, Duodenum                          (53)         (53)         (53)         (53)         (52)         (53)         
      Carcinoma, Metastatic, Uterus                                                                                     1 (2%)      
   Intestine Small, Jejunum                           (53)         (53)         (53)         (52)         (52)         (53)         
      Leiomyoma                                                                                                         1 (2%)      
   Liver                                              (53)         (53)         (53)         (52)         (53)         (53)         
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)       1 (2%)      
      Cholangiocarcinoma                                                                      1 (2%)       1 (2%)       1 (2%)      
      Cholangiocarcinoma, Multiple                                                                                      1 (2%)      
      Hepatocellular Adenoma                           1 (2%)                    1 (2%)                    2 (4%)       4 (8%)      
   Oral Mucosa                                        (52)         (53)         (52)         (53)         (53)         (53)         
      Gingival, Squamous Cell Carcinoma                1 (2%)       2 (4%)       1 (2%)                    1 (2%)       3 (6%)      
   Pancreas                                           (53)         (53)         (53)         (52)         (52)         (52)         
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)       1 (2%)      
      Acinus, Adenoma                                                                                      1 (2%)                   
      Acinus, Carcinoma                                                                                    1 (2%)                   
   Stomach, Forestomach                               (53)         (53)         (53)         (53)         (52)         (53)         
      Fibrosarcoma                                                                                                      1 (2%)      
   Stomach, Glandular                                 (53)         (53)         (53)         (53)         (52)         (53)         
      Carcinoma, Metastatic, Uterus                                                                                     1 (2%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (53)         (53)         (52)         (53)         (53)         (52)         
      Schwannoma Malignant                             1 (2%)       2 (4%)                    2 (4%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (53)         (53)         (52)         (53)         (53)         
      Adenoma                                          1 (2%)       1 (2%)                                 2 (4%)                   
      Carcinoma                                        1 (2%)                                              1 (2%)                   
   Adrenal Medulla                                    (53)         (53)         (53)         (52)         (53)         (53)         
      Pheochromocytoma Malignant                                                 1 (2%)                                             
      Pheochromocytoma Complex                         1 (2%)                                                                       
      Pheochromocytoma Benign                          4 (8%)       5 (9%)       2 (4%)       5 (10%)      1 (2%)       2 (4%)      
      Bilateral, Pheochromocytoma Benign                                                      1 (2%)                                
   Islets, Pancreatic                                 (53)         (53)         (53)         (52)         (52)         (52)         
      Adenoma                                                                    1 (2%)       1 (2%)       1 (2%)       2 (4%)      
      Carcinoma                                                                  1 (2%)                                             
   Parathyroid Gland                                  (49)         (51)         (44)         (51)         (49)         (49)         
      Adenoma                                                       2 (4%)                                                          
   Pituitary Gland                                    (53)         (53)         (53)         (53)         (53)         (53)         
      Carcinoma                                                     1 (2%)                                                          
      Pars Distalis, Adenoma                          15 (28%)     21 (40%)     23 (43%)     23 (43%)     21 (40%)     16 (30%)     
   Thyroid Gland                                      (53)         (53)         (51)         (53)         (51)         (51)         
      Bilateral, C-Cell, Adenoma                                    1 (2%)       1 (2%)       1 (2%)                                
      C-Cell, Adenoma                                 13 (25%)      9 (17%)      8 (16%)      8 (15%)      6 (12%)      7 (14%)     
      C-Cell, Carcinoma                                2 (4%)       2 (4%)       2 (4%)       2 (4%)                    1 (2%)      
      Follicular Cell, Adenoma                                      1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (51)         (53)         (53)         (50)         (53)         
      Adenoma                                                                    1 (2%)                                             
      Carcinoma, Metastatic, Mammary Gland                          1 (2%)                                                          
   Ovary                                              (53)         (53)         (53)         (52)         (52)         (53)         
      Cystadenoma                                                   1 (2%)                                                          
      Granulosa Cell Tumor Malignant                                1 (2%)                                                          
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
      Granulosa Cell Tumor Benign                                   1 (2%)       1 (2%)                                             
      Luteoma                                          1 (2%)                                                                       
      Sertoli Cell Tumor Malignant                                                            1 (2%)                                
   Uterus                                             (53)         (53)         (53)         (52)         (52)         (53)         
      Adenoma                                          2 (4%)                                                                       
      Carcinoma                                        1 (2%)       1 (2%)                    1 (2%)       5 (10%)      2 (4%)      
      Fibroma                                          1 (2%)                                                                       
      Leiomyoma                                                                               1 (2%)                                
      Polyp Stromal                                    8 (15%)      3 (6%)       5 (9%)       5 (10%)      6 (12%)      3 (6%)      
      Polyp Stromal, Multiple                          1 (2%)                                              1 (2%)       1 (2%)      
      Schwannoma Malignant                                                                    1 (2%)                    1 (2%)      
      Squamous Cell Carcinoma                                                                              1 (2%)                   
      Cervix, Polyp Stromal                                                      1 (2%)                                             
      Cervix, Sarcoma Stromal                                       1 (2%)                                                          
      Cervix, Schwannoma Malignant                                  1 (2%)                                                          
      Cervix, Squamous Cell Carcinoma                                            1 (2%)                                             
   Vagina                                             (1)          (1)          (1)                                                 
      Polyp                                                                      1 (100%)                                           
      Sarcoma Stromal                                               1 (100%)                                                        
      Squamous Cell Papilloma                          1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (53)         (53)         (53)         (53)         (53)         (53)         
   Lymph Node                                         (5)          (4)          (4)          (4)          (3)          (7)          
      Deep Cervical, Carcinoma, Metastatic,                                                                                         
          Thyroid Gland                                                          1 (25%)                                            
      Inguinal, Carcinoma, Metastatic, Mammary                                                                                      
          Gland                                                                                                         1 (14%)     
      Mediastinal, Carcinoma, Metastatic, Thyroid                                                                                   
          Gland                                                                  1 (25%)                                            
   Lymph Node, Mandibular                             (53)         (53)         (51)         (53)         (51)         (51)         
   Lymph Node, Mesenteric                             (53)         (53)         (53)         (52)         (52)         (53)         
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)                   
   Spleen                                             (53)         (53)         (53)         (52)         (52)         (51)         
      Carcinoma, Metastatic, Uterus                                                                                     1 (2%)      
   Thymus                                             (53)         (49)         (50)         (52)         (49)         (51)         
      Osteosarcoma, Metastatic, Skin                                                                                    1 (2%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (53)         (53)         (53)         (53)         (53)         (53)         
      Adenoma                                          1 (2%)       1 (2%)       2 (4%)                    1 (2%)                   
      Carcinoma                                        5 (9%)       9 (17%)     11 (21%)      2 (4%)       5 (9%)       3 (6%)      
      Carcinoma, Multiple                                           3 (6%)       2 (4%)                                             
      Fibroadenoma                                    24 (45%)     23 (43%)     23 (43%)     21 (40%)     22 (42%)     17 (32%)     
      Fibroadenoma, Multiple                          10 (19%)     12 (23%)      7 (13%)      8 (15%)     12 (23%)     13 (25%)     
      Osteosarcoma, Metastatic, Skin                                                                                    1 (2%)      
   Skin                                               (53)         (53)         (53)         (53)         (53)         (53)         
      Basal Cell Carcinoma                                                                                 1 (2%)                   
      Fibroma                                                       1 (2%)       1 (2%)       1 (2%)                    1 (2%)      
      Fibrosarcoma                                                               1 (2%)                                             
      Fibrous Histiocytoma                                                                                              1 (2%)      
      Keratoacanthoma                                                                                                   1 (2%)      
      Neural Crest Tumor                                                                                                1 (2%)      
      Neurofibroma                                                  1 (2%)                                                          
      Osteosarcoma                                                                                                      1 (2%)      
      Schwannoma Malignant                                          1 (2%)                                                          
      Subcutaneous Tissue, Hemangioma                                                         1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (53)         (53)         (53)         (53)         (53)         (53)         
      Osteosarcoma                                                  1 (2%)                                                          
   Skeletal Muscle                                                                           (2)                                    
      Rhabdomyosarcoma                                                                        1 (50%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (53)         (53)         (53)         (53)         (53)         
      Astrocytoma Malignant                                                      1 (2%)                    1 (2%)       1 (2%)      
      Carcinoma, Metastatic, Pituitary Gland                        1 (2%)                                                          
      Granular Cell Tumor Malignant                                                           1 (2%)                                
      Cranial Nerve, Squamous Cell Carcinoma,                                                                                       
          Metastatic, Oral Mucosa                                                                          1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (53)         (53)         (53)         (53)         (53)         (52)         
      Alveolar/Bronchiolar Adenoma                                                                                      1 (2%)      
      Carcinoma, Metastatic, Mammary Gland             1 (2%)                                              1 (2%)       2 (4%)      
      Carcinoma, Metastatic, Thyroid Gland             1 (2%)                    1 (2%)                                             
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)       1 (2%)      
      Cystic Keratinizing Epithelioma, Multiple                                                                         1 (2%)      
      Fibrous Histiocytoma, Metastatic, Skin                                                                            1 (2%)      
      Histiocytic Sarcoma                                                                                               1 (2%)      
      Osteosarcoma, Metastatic, Skin                                                                                    1 (2%)      
   Nose                                               (53)         (53)         (53)         (53)         (53)         (53)         
      Sarcoma                                                                    1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (53)         (53)         (52)         (53)         (52)         (52)         
      Sarcoma                                                                                                           1 (2%)      
   Harderian Gland                                    (53)         (53)         (53)         (53)         (52)         (52)         
      Carcinoma, Metastatic, Oral Mucosa                            1 (2%)                                                          
   Zymbal's Gland                                                                                         (1)                       
      Adenoma                                                                                              1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (53)         (53)         (52)         (53)         (53)         
      Lipoma                                           1 (2%)                                                                       
      Nephroblastoma                                                             1 (2%)                    1 (2%)                   
      Renal Tubule, Adenoma                                                      1 (2%)                    1 (2%)                   
   Urinary Bladder                                    (53)         (52)         (53)         (53)         (51)         (53)         
      Carcinoma, Metastatic, Uterus                                                                        1 (2%)                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(53)        *(53)        *(53)        *(53)        *(53)        *(53)         
      Histiocytic Sarcoma                                                                                               1 (2%)      
      Leukemia Mononuclear                             1 (2%)       1 (2%)                                              1 (2%)      
      Lymphoma Malignant                                                                      1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            48          49          49          44          48          46               
     Total Primary Neoplasms                           97         110         102          89          96          90               
                                                                                                                                    
   Total Animals with Benign Neoplasms                 45          45          43          42          45          41               
     Total Benign Neoplasms                            84          83          79          76          78          70               
                                                                                                                                    
   Total Animals with Malignant Neoplasms              12          20          21          13          16          16               
     Total Malignant Neoplasms                         13          27          23          13          18          19               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              2           3           1           1           3           5               
     Total Metastatic Neoplasm                          2           3           3           1           7          14               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                              1               
     Total Uncertain Neoplasms                                                                                      1               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50                                                                            
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                25                                                                            
    Natural Death                                     10                                                                            
  Survivors                                                                                                                         
    Terminal Sacrifice                                15                                                                            
                                                                                                                                    
  Animals Examined Microscopically                    50                                                                            
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Rectum                            (50)                                                                          
      Squamous Cell Carcinoma, Metastatic, Uterus      1 (2%)                                                                       
   Liver                                              (50)                                                                          
      Hepatocellular Adenoma                           1 (2%)                                                                       
   Oral Mucosa                                        (50)                                                                          
      Gingival, Squamous Cell Carcinoma                3 (6%)                                                                       
   Pancreas                                           (49)                                                                          
      Adenoma                                          1 (2%)                                                                       
      Carcinoma                                        1 (2%)                                                                       
   Stomach, Forestomach                               (50)                                                                          
      Squamous Cell Papilloma                          1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (48)                                                                          
      Adenoma                                          1 (2%)                                                                       
   Adrenal Medulla                                    (48)                                                                          
      Pheochromocytoma Benign                          1 (2%)                                                                       
   Pituitary Gland                                    (49)                                                                          
      Pars Distalis, Adenoma                          13 (27%)                                                                      
   Thyroid Gland                                      (48)                                                                          
      C-Cell, Adenoma                                  5 (10%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (47)                                                                          
      Luteoma                                          1 (2%)                                                                       
   Uterus                                             (49)                                                                          
      Carcinoma                                        1 (2%)                                                                       
      Hemangioma                                       1 (2%)                                                                       
      Polyp Stromal                                    4 (8%)                                                                       
      Cervix, Squamous Cell Carcinoma                  1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Thymus                                             (49)                                                                          
      Thymoma Malignant, Metastatic, Mammary Gland     1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (50)                                                                          
      Adenoma                                          2 (4%)                                                                       
      Carcinoma                                        5 (10%)                                                                      
      Fibroadenoma                                    25 (50%)                                                                      
      Fibroadenoma, Multiple                           9 (18%)                                                                      
   Skin                                               (50)                                                                          
      Basal Cell Carcinoma                             1 (2%)                                                                       
      Fibroma                                          1 (2%)                                                                       
      Fibrosarcoma                                     1 (2%)                                                                       
      Sarcoma                                          1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)                                                                          
      Fibrosarcoma, Metastatic, Skin                   1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)                                                                          
      Squamous Cell Carcinoma, Metastatic, Uterus      1 (2%)                                                                       
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 96007-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03  
Route: GAVAGE                                                                                                     Time: 11:23:01  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            43                                                                           
     Total Primary Neoplasms                           80                                                                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                 40                                                                           
     Total Benign Neoplasms                            66                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              12                                                                           
     Total Malignant Neoplasms                         14                                                                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              3                                                                           
     Total Metastatic Neoplasm                          4                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------